Arrowhead Pharmaceuticals Advances Alzheimer's Drug Push With Promising Early Clinical Results
Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.
Stocks · News reference
Arrowhead Announces Interim Results From Ongoing Phase 1/2a Study Of ARO-MAPT, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Alzheimer’s Disease And Other Tauopathies
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Arrowhead Reports First Clinical Validation Of TRiM Platform As ARO-MAPT Achieves Up To 73% Mean and 85% Maximum Tau Reduction
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on
Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities
The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.